Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
59 hedge funds and large institutions have $69M invested in Enzo Biochem, Inc. in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 15 closing their positions.
9% less funds holding
Funds holding: 65 → 59 (-6)
17% less capital invested
Capital invested by funds: $82.9M → $69M (-$13.9M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
52% less call options, than puts
Call options by funds: $205K | Put options by funds: $430K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$1.09M |
| 2 |
VCA
VIEX Capital Advisors
Sunny Isles Beach,
Florida
|
+$770K |
| 3 |
CCM
Corsair Capital Management
New York
|
+$200K |
| 4 |
Bank of New York Mellon
New York
|
+$196K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
-$6.13M |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.54M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$847K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$775K |
| 5 |
E
Ergoteles
New York
|
-$532K |
ENZ Hedge Fund Activity: Q4 2021 in Review
59 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2021, worth a combined $69M — down 17% from $82.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ENZ and 9 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 9 added.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $1.09M. The largest seller was Evermore Global Advisors, exiting entirely with an estimated $6.13M sold.
- 59 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2021, down from 65 in Q3 2021.
- Funds reported $69M of Enzo Biochem, Inc. stock for Q4 2021, down 17% quarter-over-quarter.
- 9 funds opened new Enzo Biochem, Inc. positions in Q4 2021 and 15 closed out, a net change of -6 holders.
- The largest Enzo Biochem, Inc. buyer in Q4 2021 was Boothbay Fund Management, an estimated $1.09M added.
- The largest Enzo Biochem, Inc. seller in Q4 2021 was Evermore Global Advisors, an estimated $6.13M sold.
Based on aggregated 13F filings for Q4 2021.